Code: rbdg0010
Pages: 185
Tables: 48
Figures: 21

Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook

The key factor in the current scenario for next-generation omics-based diagnostic technologies is the level of accuracy in the results, followed by the capacity to detect early, and cost. Cost currently remains a major constraint, as people and healthcare institutes are skeptical of investing in technologies that have not provided very wide and acceptable results. The impact of cost constraints will diminish as the cost/value benefit is established. The future market will demand reliability, which means reproducible results on standard equipment, and techniques with less deviation across laboratories and methodologies. The importance of accuracy remains constant. Industry participants will continue to position their diagnostic products based on accuracy levels. Emphasis will also remain on its capacity to test the probability of disease as early as possible through a non-invasive method of diagnosis. The report discusses drivers, restraints, challenges and opportunities and market estimates of the global diagnostics market in genomics, proteomics and metabolomics on the basis of: Technologies, Applications, Strategic issues and innovations.

Table of contents | Buy online | More information

Code: rbdg0009
Pages: 180
Tables: 32
Figures: 31

The Future of Cardiovascular Diagnostics: Impact of technological advances on growth opportunities and future market outlook

Cardiovascular disease (CVD) is one of the leading causes of death, accounting for around a third of all deaths. The identification and application of novel cardio biomarkers has helped cardiologists to stratify high risk patients whilst the advances in diagnostic imaging has lead to improvements in the speed and resolution of images, increasing its clinical utility in the detection, diagnosis and treatment of CVD whilst minimizing the need for invasive procedures. Diagnostic imaging provides cardiologists with detailed information upon which an accurate diagnosis can be made. Currently no single imaging test is superior to all the others and a variety of imaging modalities may be used to diagnose CVD. Meanwhile in vitro diagnostic (IVD) companies have launched a range of assay platforms including laboratory bases ultra high through systems to point of care (PoC) bench top and hand held devices. Meanwhile tremendous advances have been made in all imaging modalities leading to an increase in the speed and resolution of cardiovascular imaging procedures whilst reducing the use of ionizing radiation and contrast agents. Despite the success of both IVD and diagnostic imaging technologies these products and services continue to come under scrutiny from healthcare providers and the need to demonstrate comparative effectiveness and clinical outcome is critical if the medical community is to continue to have access to the appropriate diagnostic tools to enhance the diagnosis and treatment of the worlds biggest killers heart disease and stroke.

Table of contents | Buy online | More information

Code: rbdg0008
Pages: 283
Tables: 33
Figures: 09

Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape

Diagnostic practice is undergoing a quiet revolution, with IVD tests moving out of the centralized hospital laboratory to point of care testing (POCT) locations. POC tests are more expensive than lab-based tests, but promise to reduce the overall cost of healthcare while improving the quality of outcomes. They are thus attractive to manufacturers and increasingly in demand by physicians, patients, and healthcare providers. This report explores the opportunities for POC testing provided by recent technology improvements, disease trends, and new marketing channels. It examines established and emerging health-related applications of POC diagnostics based on immunoassays, clinical chemistry, and nucleic acid testing. Within each POCT market sector, leading companies and their strategies and products are examined.

Table of contents | Buy online | More information

Code: rbdg0007
Pages: 141
Tables: 14
Figures: 20

Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook

Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors – all of whom want more effective treatments and value for money. ‘Innovations in Oncology Diagnostics’ is a new report published by Business Insights that analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. This report also identifies the key challenges facing innovative diagnostics companies.

Table of contents | Buy online | More information

Code: rbdg0006
Pages: 253
Tables: 16
Figures: 3

Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook

Microarrays and biochips are small devices capable of detecting and measuring large numbers of biomarkers simultaneously. Although microarrays have been in research use for over a decade it is only recently that they have moved towards meeting the requirements of the clinical and regulatory communities with the first DNA microarray test being approved by the US FDA in 2007. Further development of microarrays heralds the introduction of faster diagnosis times and will further enable personalized medicine. This report covers future developments in key segments of the microarray market including DNA, protein, tissue and cell microarrays and lab-on-a-chip technologies, providing market forecasts to 2013.

Table of contents | Buy online | More information

Code: rbdg0005
Pages: 141
Tables: 9
Figures: 11

Expanding Applications of Personalized Medicine: Use of biomarkers in prognostic, predictive and pharmacogenetic tests in a targeted approach

Over the past decade, several significant advances in targeted therapies have improved the ability to treat certain cancers, the most notable early successes have been trastuzumab in breast cancer and imatinib in chronic myelogenous leukemia. Recently, several important breakthroughs have occurred, including the identification of a mechanism of resistance to EGFR monoclonal antibodies in colorectal cancer, which may be followed by further predictive tests leading to a reduction in the use of ineffective therapies. ‘Expanding Applications of Personalized Medicine’ is a new report published by Business Insights that provides an in-depth analysis of current applications in personalized medicine, and highlights future opportunities and clinical advances.

Table of contents | Brochure/order form | Buy online | More information

Code: rbdg0004
Pages: 152
Tables: 16
Figures: 38

Innovations in Medical Imaging: Technological advances, growth opportunities and future market outlook

Medical imaging technologies are widely used in clinical diagnosis to guide therapeutic and surgical intervention and to monitor disease progression, recurrence and treatment response and to improve surgical navigation. A plethora of imaging modalities are available to the medical community to provide anatomical and functional information. Extensive research indicates that the application of medical imaging may lead to significant reduction in healthcare costs by increasing the speed of diagnosis, avoiding the need for expensive treatments and surgical procedures and reducing mortality rate through early screening programs.

Table of contents | Buy online | More information

Code: rbdg0003
Pages: 115
Tables: 6
Figures: 14

Key Trends In Drug-diagnostic Co-development: Identifying collaborative opportunities and navigating regulatory challenges

‘Key Trends in Drug-Diagnostic Co-Development’ is a new report published by Business Insights that explores the potential for applying genomic-based diagnostics to new drug developments, and the resultant implications for the pharma/biotech and diagnostic industries. This report examines the commercial and regulatory challenges facing drug-diagnostic combinations and evaluates emerging business models to identify the most effective forms of pharmacodiagnostic partnership. This report also reviews 28 collaborative agreements for the co-development of drug-diagnostics and determines which combinations can be expected to result in commercial products in the near future.

Table of contents | Brochure/order form | Buy online | More information

Code: rbdg0002
Pages: 136
Tables: 20
Figures: 7

Innovations in In-Vitro Diagnostics: New technologies, growth opportunities, and the future market outlook

‘Innovations in In-Vitro Diagnostics’ is a new report published by Business Insights that provides an in-depth analysis of emerging opportunities and potential clinical advances across the diagnostics markets of coronary heart disease, heart failure, bacterial infections and viral infections. This report explores the major trends and issues that are shaping the development of novel diagnostics and assesses the future prospects of leading innovations. The market segments with the greatest growth opportunities are identified and the competitive landscape of the market is also assessed, with profiles of nine major diagnostics companies, based on market presence, R&D focus, acquisitions, historical sales and number of immunoanalyzers.

Table of contents | Brochure/order form | Buy online | More information

Code: rbdg0001
Pages: 160
Tables: 58
Figures: 29

The Top Ten Global In-Vitro Diagnostics Companies: Positioning, performance and SWOT analyses

‘The Top Ten Global In-Vitro Diagnostics Companies’ is a new report published by Business Insights that that explores the global competitive landscape of the IVD industry. This report analyses the size and structure of the market and identifies the latest developments in service offerings, new technologies, strategic approaches and competitive dynamics amongst leading companies. This report assesses the opportunities and threats facing the top 10 IVD companies in the future, and examines their current structure, financial performance, growth strategies and R&D activity. Growth forecasts for key products and regions are also provided. 

Table of contents | Brochure/order form | Buy online | More information